Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Reperfusion Therapies and In-Hospital Outcomes for St-Elevation Myocardial Infarction in Europe: The Acvc-Eapci Eorp Stemi Registry of the European Society of Cardiology Publisher Pubmed



Zeymer U1 ; Ludman P2 ; Danchin N3 ; Kala P4 ; Laroche C5 ; Sadeghi M6 ; Caporale R7 ; Shaheen SM8 ; Legutko J9 ; Iakobsishvili Z11 ; Alhabib KF12 ; Motovska Z13 ; Studencan M14 ; Mimoso J15 Show All Authors
Authors
  1. Zeymer U1
  2. Ludman P2
  3. Danchin N3
  4. Kala P4
  5. Laroche C5
  6. Sadeghi M6
  7. Caporale R7
  8. Shaheen SM8
  9. Legutko J9
  10. Iakobsishvili Z11
  11. Alhabib KF12
  12. Motovska Z13
  13. Studencan M14
  14. Mimoso J15
  15. Becker D16
  16. Alexopoulos D17
  17. Kereseselidze Z18
  18. Stojkovic S19
  19. Zelveian P20
  20. Goda A21
  21. Mirrakhimov E22, 23
  22. Bajraktari G24
  23. Alfarhan H25
  24. Serpytis P26
  25. Raungaard B27
  26. Marandi T28
  27. Moore AM29
  28. Quinn M30
  29. Karjalainen PP31
  30. Tatuchitolu G32
  31. Gale CP33
  32. Maggioni AP5, 34
  33. Weidinger F35
  34. Becker D16
  35. Quinn M30
  36. Mirrakhimov E22, 23
  37. Becker D16
  38. Moore AM29
Show Affiliations
Authors Affiliations
  1. 1. Klinikum der Stadt Ludwigshafen and Institut fur Herzinfarktforschung, Bremserstraße 79, Ludwigshafen am Rhein, 67063, Germany
  2. 2. Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston 1, Birmingham, B15 2TT, United Kingdom
  3. 3. Hopital Europeen Georges Pompidou, Service de Cardiologie, 20 Rue Leblanc, Paris, 75015, France
  4. 4. University Hospital Brno, Medical Faculty of Masaryk University, Dept of Internal Medicine and Cardiology, Kamenice 5, Brno, Bohunice, 625 00, Czech Republic
  5. 5. EURObservational Research Programme, European Society of Cardiology, European Heart House, 2035 Route des Colles, Sophia Antipolis, France
  6. 6. Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Shahid Rahmani Alley, Moshtagh Sevom Street, Isfahan, Iran
  7. 7. Interventional Cardiology Unit, Annunziata Civil Hospital, Via Migliori 1, Cosenza, 87100, Italy
  8. 8. Ain Shams University, Ramsis Street Abbassia Square, Cairo, Egypt
  9. 9. Jagiellonian University Medical College
  10. 10. Institute of Cardiology, Department of Interventional Cardiology, John Paul II Hospital, Pradnicka 80, Krakow, 31-202, Poland
  11. 11. Rabin Medical Center, Zeev Jabotinsky St 39, Petah Tikva, 49100, Israel
  12. 12. Department of Cardiac Sciences, King Fahad Cardiac Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia
  13. 13. Cardiocenter, Third Faculty of Medicine Charles Univ. and Univ. Hospital Kralovske Ruska 2411, Vinohrady 10, Praha, 100 00, Czech Republic
  14. 14. Teaching Hospital of J.A. Reiman, Cardiocentre Presov, Jana Holleho 5898/14, Presov, 081 81, Slovakia
  15. 15. Centro Hospitalar e Universitario Do Algarve, R. Leao Penedo, Faro, 8000-386, Portugal
  16. 16. Deputy-Director of the Heart and Vascular Center of Semmelweis University, Gaal Jozsef ut 9, Budapest, 1122, Hungary
  17. 17. National and Kapodistrian University of Athens, Attikon University Hospital, Rimini 1 Chaidari, 124 62, Greece
  18. 18. Chapidze Emergency Cardiology Center, Didube-Chugureti District, Nino Javakhishvili str., Tbilisi, 0159, Georgia
  19. 19. Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  20. 20. Scientific Research Institute of Cardiology Named after Levon Hovhannisyan, Paruyr Sevaki St., 5 Building (Kanaker-Zeytun adm. district), Yerevan, 0014, Armenia
  21. 21. Cardiology i and Cardiology Ii, University Hospital Center Mother Theresa, Rruga e Dibres 372 AL, Tirana, 1000, Albania
  22. 22. Kyrgyz State Medical Academy, 92 Akhunbayev St, Bishkek, Kyrgyzstan
  23. 23. National Center of Cardiology and Internal Medicine, Togolok Moldo Str., Bishkek, 720040, Kyrgyzstan
  24. 24. Medical Faculty, University of Prishtina Hasan Prishtina, University Clinical Centre of Kosova, Pristina, 10000, Serbia
  25. 25. Iraqi Scientific Council of Cardiology, Baghdad Heart Center Medical City, Baghdad, Iraq
  26. 26. Vilnius University Faculty of Medicine Hospital Santaros Klinikos, Santariskiu g. 2, Vilnius, 08410, Lithuania
  27. 27. Aalborg University Hospital, Department of Cardiology, Hobrovej 18-22, Aalborg, 9100, Denmark
  28. 28. North Estonia Medical Centre, J. Sutiste tee 19, Tallinn, 13419, Estonia
  29. 29. Mater Dei Hospital, Triq Dun Karm, Msida, MSD2090, Malta
  30. 30. St Vincent's University Hospital, Merrion Rd, Dublin 4, D04 N2E0, Ireland
  31. 31. Satakunta Cental Hospital, Sairaalantie 3, Pori, 28500, Finland
  32. 32. Spitalul Clinic de Urgenta Floreasca, Calea Floreasca 8, Bucuresti, 014461, Romania
  33. 33. Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds School of Medicine, Worsley Building, University of Leeds, Leeds, LS2 9JT, United Kingdom
  34. 34. Maria Cecilia Hospital, GVM Care and Research, Via Corriera, 1 RA, Cotignola, 48033, Italy
  35. 35. Hospital Rudolfstiftung, Juchgasse 25, Wien, 1030, Austria

Source: European Heart Journal Published:2021


Abstract

Aims: The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). Methods and results: Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24 h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0-100%), fibrinolysis (18.8%; 0-100%), and no reperfusion therapy (9.0%; 0-75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.5-5.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8-97.5%) for the performance of reperfusion therapy of all patients with STEMI <12 h and 54.4% (region range 37.1-70.1%) for timely reperfusion. Conclusions: The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality. © 2021 Published on behalf of the European Society of Cardiology. All rights reserved.
Related Docs
View other Related Docs
1. Reperfusion Therapy for St-Elevation Myocardial Infarction Complicated by Cardiogenic Shock: The European Society of Cardiology Eurobservational Programme Acute Cardiovascular Care-European Association of Pci St-Elevation Myocardial Infarction Registry, European Heart Journal: Acute Cardiovascular Care (2022)
2. Care of Patients With St-Elevation Myocardial Infarction: An International Analysis of Quality Indicators in the Acute Coronary Syndrome Stemi Registry of the Eurobservational Research Programme and Acvc and Eapci Associations of the European Society of Cardiology in 11 462 Patients, European Heart Journal: Acute Cardiovascular Care (2023)
3. The Comparison of Procedural and Clinical Outcomes of Thrombolytic-Facilitated and Primary Percutaneous Coronary Intervention in Patients With Acute St-Elevation Myocardial Infarction (Stemi): Findings From Prove/Acs Study, ARYA Atherosclerosis (2020)
4. Background and Design of a 5-Year St Elevation Myocardial Infarction Cohort in Isfahan, Iran: Semi-Ci Study, ARYA Atherosclerosis (2022)
5. Clinical, Laboratory, and Procedural Predictors of Slow Flow/No Reflow Phenomenon After Emergency Percutaneous Coronary Interventions in St-Elevated Myocardial Infarction, Egyptian Heart Journal (2024)
6. The Assessment of No-Reflow Phenomenon Incidence in Early Versus Delayed Percutaneous Coronary Intervention Following a Primary Fibrinolysis, ARYA Atherosclerosis (2024)
7. Clinical Characteristics, Management and 1-Year Outcomes of Patients With Acute Coronary Syndrome in Iran: The Iranian Project for Assessment of Coronary Events 2 (Ipace2), BMJ Open (2015)
8. Utilization of Evidence-Based Therapy for Acute Coronary Syndrome in High-Income and Low/Middle-Income Countries, American Journal of Cardiology (2014)
Experts (# of related papers)
View all Related Experts
Masoumeh Sadeghi (42)
Nizal Sarrafzadegan (23)
Other Related Docs
9. A Global Overview of Acute Coronary Syndrome Registries: A Systematic Review, Current Problems in Cardiology (2023)
10. The Pragmatic Role of Covid-19 on the Thrombus Grade of Patients With Contemporary St-Segment-Elevation Myocardial Infarction, Journal of Tehran University Heart Center (2022)
11. Predictors of Mortality for Patients With St-Elevation Myocardial Infraction After 2-Year Follow-Up: A St-Elevation Myocardial Infarction Cohort in Isfahan Study, Advanced Biomedical Research (2022)
12. Long-Term Outcome and Prognostic Value of Angiographic Slow/No-Reflow Phenomenon After Emergency Percutaneous Coronary Intervention for St-Elevation Myocardial Infarction, Coronary Artery Disease (2024)
13. Immediate Results and Six-Month Outcomes After Percutaneous Coronary Intervention in a Referral Heart Center in Isfahan, Iran, ARYA Atherosclerosis (2011)
14. Blood Group Types and Clinical, Procedural, and Adverse Outcomes in St-Elevated Myocardial Infarction Patients: A 3-Year Cohort in Iran, Journal of Research in Medical Sciences (2023)
15. The Role of Manual Thrombectomy in Cardiovascular Outcome Among Patients With Total Cutoff Vessel Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention, ARYA Atherosclerosis (2017)
16. Does Adjunctive Prophylactic Intracoronary Infusion of Low Dose Alteplase Prevent No-Reflow Phenomenon During Primary Percutaneous Coronary Intervention?, ARYA Atherosclerosis (2023)
17. Persian Registry of Cardiovascular Disease (Prove): Design and Methodology, ARYA Atherosclerosis (2017)
18. Effectiveness of Tenecteplase Versus Streptokinase in Treatment of Acute Myocardial Infarction: A Meta-Analysis, Tehran University Medical Journal (2018)
19. Evaluating the Guidelines Adherence in the Management of Nste-Acs Referred to Shahid Chamran Hospital Within Six-Month Period in 2021: A Brief Report; [بررسی تطابق دارودرمانی بیماران دچار حمله قلبی Nste-Acs مراجعه کرده به بیمارستان شهید چمران اصفهان با گایدلاین مربوطه در شش ماهه اول سال 1400: یک گزارش کوتاه], Tehran University Medical Journal (2023)
20. Is Cardiac Rehabilitation After Pci As Effective As Cabg? the First Experience From the Eastern Mediterranean Region Cardiac Rehabilitation Registry, ARYA Atherosclerosis (2024)
21. The Pattern of In-Hospital Mortality of Myocardial Infarction and Associated Factors in Iran: A National Study, Journal of Isfahan Medical School (2015)
22. The Effect of Intracoronary Versus Intralesional Injection of Eptifibatide on Myocardial Perfusion Outcomes During Primary Percutaneous Coronary Intervention in Acute St-Segment Elevation Myocardial Infarction; a Randomized Clinical Trial Study, ARYA Atherosclerosis (2019)
23. Long-Term Clinical Outcomes of the Left Ventricular Thrombus in Patients With St Elevation Anterior Myocardial Infarction, ARYA Atherosclerosis (2015)
24. Assessment of Metabolic Risk Factors and Heart-Healthy Lifestyle in Atherosclerotic Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention After a 6-Month Follow-Up, Advanced Biomedical Research (2022)
25. Cardiovascular Disease in the Eastern Mediterranean Region: Epidemiology and Risk Factor Burden, Nature Reviews Cardiology (2018)
26. Anti-Streptokinase Antibody Detection Before and Immediately After Streptokinase Therapy in Patients With Myocardial Infarction, Iranian Journal of Immunology (2006)
27. Comparison of Survival Rate and Complications of Percutaneous Coronary Intervention, Coronary Artery Bypass Graft, and Medical Treatment in Patients With Left Main And/Or Three Vessel Diseases, ARYA Atherosclerosis (2020)
28. Comparison of No-Reflow Phenomenon After Percutaneous Coronary Intervention for Acute Myocardial Infarction Between Smokers and Nonsmokers, Journal of Research in Medical Sciences (2014)
29. Drop-Out Predictors in Cardiac Rehabilitation Programmes and the Impact of Sex Differences Among Coronary Heart Disease Patients in an Iranian Sample: A Cohort Study, Clinical Rehabilitation (2007)
30. Association Between the Platelet-To-Lymphocyte Ratio and the No-Reflow Phenomenon and Thrombolysis in Myocardial Infarction Flow 3 After Primary Percutaneous Coronary Intervention in Patients With St-Segment Elevation Myocardial Infarction, Iranian Heart Journal (2017)
31. Prediction of Short-Term Clinical Outcome of Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome Through Myeloperoxidase Levels, ARYA Atherosclerosis (2014)
32. Factors Affecting Outcome of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction, ARYA Atherosclerosis (2013)
33. Comparing Efficacy of Receiving Different Doses of Eptifibatide in Bleeding After Percutaneous Coronary Intervention in Patients With Myocardial Infarction, ARYA Atherosclerosis (2019)
34. Differences Between the Characteristics of Ihd Patients Undergoing Different Treatment Modalities Who Adhere to Cardiac Rehabilitation Programs, Iranian Heart Journal (2014)
35. Impact of Allopurinol Pretreatment on Coronary Blood Flow and Revascularization Outcomes After Percutaneous Coronary Intervention in Acute Stemi Patients: A Randomized Double Blind Clinical Trial, ARYA Atherosclerosis (2023)
36. Promoting Patient Utilization of Outpatient Cardiac Rehabilitation: A Joint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation Position Statement, International Journal of Cardiology (2020)
37. The Correlation Between Early Complications of Percutaneous Coronary Intervention and High Sensitive C-Reactive Protein, ARYA Atherosclerosis (2013)
38. Analysis of Traditional Risk Factors on St-Segment Elevation Myocardial Infarction Characteristics; [بررسی عوامل خطر سنتی مرتبط با ویژگیهای بالینی بیماران انفارکتوس میوکارد با بالارونده قطعه St], Journal of Isfahan Medical School (2024)
39. Development of the First Iranian Clinical Practice Guidelines for the Diagnosis, Treatment, and Secondary Prevention of Acute Coronary Syndrome, Journal of Research in Medical Sciences (2024)
40. Determination of Characteristics and Data Elements Requirements in National Acute Coronary Syndrome Registries for Postdischarge Follow-Up, Current Problems in Cardiology (2023)
41. Prevalence of Return to Work in Cardiovascular Patients After Cardiac Rehabilitation: A Systematic Review and Meta-Analysis, Current Problems in Cardiology (2022)
42. Predictive Factors of Short-Term Survival From Acute Myocardial Infarction in Early and Late Patients in Isfahan and Najafabad, Iran, ARYA Atherosclerosis (2016)
43. Effects of Cardiac Rehabilitation on Inflammatory Biomarkers in Unstable Ischemic Heart Disease Patients Following Percutaneous Coronary Intervention: A Randomized Controlled Study, Coronary artery disease (2024)
44. Long-Term Hospital Readmission After St-Elevation Myocardial Infarction: A 3-Year Follow-Up From the Semi-Ci Study, Journal of Tehran University Heart Center (2022)
45. Non-Administration of Thrombolytic Agents in Acute Myocardial Infarction Patients in Hajar Hospital, Shahrekord, Iran: Prevalence Rate and Causes, ARYA Atherosclerosis (2013)
46. Design and Methodology of Heart Failure Registry: Results of the Persian Registry of Cardiovascular Disease, ARYA Atherosclerosis (2019)
47. Evaluating the Impact of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Intermediate Coronary Artery Lesions on the Mode of Treatment and Their Outcomes: An Iranian Experie, ARYA Atherosclerosis (2015)
48. Audit and Quality Assessment of National Persian Registry of Cardiovascular Disease(N-Prove) in Terms of Comorbidities, Angiography, and Angioplasty Characteristics in Iran, ARYA Atherosclerosis (2024)
49. Medical Therapy Versus Percutaneous Coronary Intervention or Coronary Artery Bypass Graft in Stable Coronary Artery Disease; a Systematic Review and Meta-Analysis of Randomized Clinical Trials, ARYA Atherosclerosis (2022)
50. Cardiovascular and Bleeding Events of Ticagrelor Monotherapy After Short-Term Dual Antiplatelet Therapy (Dapt) in Diabetics and Non-Diabetics Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis, ARYA Atherosclerosis (2023)